A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Use of the diagonal mattress suture to prevent dog-ear formation

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata Yong Hyun Jang, MD,

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

ATX-101 for reduction of submental fat: A phase III randomized controlled trial Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

A girl with a solitary red bulla

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients Lucy Y. Liu, BA, Brittany.

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Baldness reversed by chemotherapy

Focal nail dystrophy in a cutaneous nerve distribution after trauma

ATX-101 for reduction of submental fat: A phase III randomized controlled trial Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Permanent chemotherapy-induced alopecia: A review

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Reply to: “Comment on ‘Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary.

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Alopecia areata Journal of the American Academy of Dermatology

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Androgenetic Alopecia in Women

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss Elise A. Olsen, MD, Douglas Canfield, BS Journal.

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Skin manifestations associated with chronic recurrent multifocal osteomyelitis in a 9- year-old girl Frank Bachmann, MD, Karola Stieler, MD, Natalie Garcia.

Medicaid acceptance among pediatric dermatologists

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families Lucy Y. Liu,

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Modification of the nail psoriasis severity index

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled.

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

A grayscale photograph with high dynamic range taken under a Wood's lamp for better recognition of vitiligo lesions Jung Min Bae, MD, PhD, Tae Young.

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Efficacy and safety of antiscabietic agents: A systematic review and network meta- analysis of randomized controlled trials Kunlawat Thadanipon, MD, Thunyarat.

The JAAD adopts the CONSORT statement

Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia Juan Jimenez-Cauhe, MD, David Saceda-Corralo, MD, PhD, Rita Rodrigues-Barata,

Photosensitive lichenoid drug eruption to capecitabine

Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals Cynthia Haddad, PharmD, MSc, Odette Berline.

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women Ulrike Blume-Peytavi, MD, PhD, Kathrin Hillmann, MD, Ekkehart Dietz, PhD, Douglas Canfield, Natalie Garcia Bartels, MD Journal of the American Academy of Dermatology Volume 65, Issue 6, Pages 1126-1134.e2 (December 2011) DOI: 10.1016/j.jaad.2010.09.724 Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Participant disposition. One drug-unrelated serious adverse event (SAE) in 5% minoxidil topical foam (MTF) population. AE, Adverse event; LTF, lost to follow-up; MTS, minoxidil topical solution; SP, subject preference. Journal of the American Academy of Dermatology 2011 65, 1126-1134.e2DOI: (10.1016/j.jaad.2010.09.724) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Nonvellus target area hair count (TAHC). MTF, Minoxidil topical foam; MTS, minoxidil topical solution. Journal of the American Academy of Dermatology 2011 65, 1126-1134.e2DOI: (10.1016/j.jaad.2010.09.724) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Nonvellus target area hair width (TAHW). MTF, Minoxidil topical foam; MTS, minoxidil topical solution. Journal of the American Academy of Dermatology 2011 65, 1126-1134.e2DOI: (10.1016/j.jaad.2010.09.724) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Nonvellus target area hair count (TAHC) at week 24 change from baseline is lower with increasing severity of Savin score among all participants randomized to 5% minoxidil topical foam or 2% minoxidil topical solution. Lowest TAHC is obtained in women with highest Savin score (D6) (Savin scale ranges from D1-D8, current study recruited women with Savin grade D3-D6). Journal of the American Academy of Dermatology 2011 65, 1126-1134.e2DOI: (10.1016/j.jaad.2010.09.724) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

Fig 5 Global change in hair volume based on global photographs of scalp midpattern comparing baseline and week 24 by investigators' (A) and participants' (B) evaluation (–3 = greatly decreased, –2 = moderately decreased, –1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, and +3 = greatly increased). MTF, Minoxidil topical foam; MTS, minoxidil topical solution. Journal of the American Academy of Dermatology 2011 65, 1126-1134.e2DOI: (10.1016/j.jaad.2010.09.724) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

Fig 6 Distribution of responses to statement 6 of participants' questionnaire 2 (“The treatment does not interfere with styling my hair”). Responses range from 1 = totally disagree to 7 = totally agree. MTF, Minoxidil topical foam; MTS, minoxidil topical solution; ND, no data. Journal of the American Academy of Dermatology 2011 65, 1126-1134.e2DOI: (10.1016/j.jaad.2010.09.724) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions